Drug Trial Radar · NCT07783425
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,375
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Sep 8, 2028
Study completion Jun 15, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking participants who: * Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD. The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48. Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.
Conditions
- Atopic Dermatitis
Interventions
TilrekimigDrug
Subcutaneous Injections at required timepoints
DupilumabDrug
Subcutaneous Injections at required timepoints based on weight and age.
Placebo for TilrekimigOther
Subcutaneous Injections at required timepoints
Placebo for DupilumabOther
Subcutaneous Injections at required timepoints during initial treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in the proportion of Eczema Area and Severity Index (EASI)75 responders between tilrekimig versus placebo.Time frame: Week 16
- Difference in the proportion of validated Investigator Global Assessment- Atopic Dermatitis (vIGA-AD) 0/1 responders between tilrekimig versus placebo.Time frame: Week 16
Locations
50 sites in 4 countries. Site status is shown where the registry gives one.
AllerVie Clinical Research
Birmingham, Alabama · Recruiting
Cahaba Dermatology & Skin Health Center
Birmingham, Alabama · Not yet recruiting
Alliance Dermatology & MOHS Center
Phoenix, Arizona · Recruiting
Dermatology Trial Associates, Inc.
Bryant, Arkansas · Recruiting
Kern Research, Inc.
Bakersfield, California · Recruiting
First OC Dermatology Research Inc
Fountain Valley, California · Not yet recruiting
Marvel Clinical Research
Huntington Beach, California · Recruiting
Avance Clinical Trials
Laguna Niguel, California · Recruiting
California Allergy & Asthma Medical Group
Los Angeles, California · Recruiting
Northridge Clinical Trials, LLC
Northridge, California · Recruiting
Wolverine Clinical Trials
Santa Ana, California · Not yet recruiting
Direct Helpers Research Center
Hialeah, Florida · Recruiting
Research Associates of South Florida, LLC
Miami, Florida · Recruiting
Global Health Research Center, Inc.
Miami Lakes, Florida · Recruiting
Clinical Neuroscience Solutions, LLC
Orlando, Florida · Recruiting
Advanced Clinical Research Institute
Tampa, Florida · Not yet recruiting
Skin Care Physicians of Georgia
Macon, Georgia · Recruiting
Marietta Dermatology Clinical Research, Inc.
Marietta, Georgia · Recruiting
Treasure Valley Medical Research
Boise, Idaho · Not yet recruiting
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana · Recruiting
Maryland Laser Skin and Vein
Hunt Valley, Maryland · Recruiting
Revival Research Institute, LLC
Troy, Michigan · Not yet recruiting
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan · Recruiting
Empire Dermatology
East Syracuse, New York · Not yet recruiting
Vital Prospects Clinical Research Institute., PC
Tulsa, Oklahoma · Recruiting
Oregon Medical Research Center
Portland, Oregon · Not yet recruiting
Best Skin Research, LLC
Camp Hill, Pennsylvania · Not yet recruiting
Clinical Neuroscience Solutions, LLC.
Memphis, Tennessee · Recruiting
Arlington Research Center
Arlington, Texas · Recruiting
Dermatology Treatment and Research Center
Dallas, Texas · Recruiting
Derm Texas
Dallas, Texas · Recruiting
Stryde Research-Epiphany Dermatology
Southlake, Texas · Not yet recruiting
Complete Dermatology
Sugar Land, Texas · Recruiting
Alexandria Associates in Dermatology
Arlington, Virginia · Recruiting
Innovaderm Research Inc
Montreal, Quebec, Canada · Not yet recruiting
Katahira Dermatology Urology Clinic
Kagoshima, Japan · Recruiting
Okayama University Hospital
Okayama, Japan · Not yet recruiting
Pansy Skin Clinic
Saitama, Japan · Not yet recruiting
Japan Community Healthcare Organization Chukyo Hospital
Nagoya, Aichi-ken, Japan · Not yet recruiting
Iwate Medical University Hospital
Yahaba-cho, Iwate, Japan · Not yet recruiting
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.